XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Recommendation of “Moderate Buy” by Analysts

XOMA Royalty Corporation (NASDAQ:XOMA) has been assigned an average rating of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $61.60.

A number of equities research analysts have weighed in on XOMA shares. HC Wainwright lowered their price target on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Zacks Research raised XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. UBS Group set a $76.00 target price on XOMA Royalty in a research report on Tuesday, December 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 29th. Finally, TD Cowen raised shares of XOMA Royalty to a “hold” rating in a research note on Friday, February 13th.

Insider Activity at XOMA Royalty

In other XOMA Royalty news, CEO Owen Hughes bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were bought at an average price of $25.05 per share, for a total transaction of $2,505,000.00. Following the transaction, the chief executive officer directly owned 102,000 shares in the company, valued at $2,555,100. This trade represents a 5,000.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 9.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of XOMA. JPMorgan Chase & Co. boosted its holdings in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares during the period. Russell Investments Group Ltd. lifted its position in XOMA Royalty by 3,436.4% in the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 756 shares during the last quarter. State of Alaska Department of Revenue bought a new stake in XOMA Royalty in the fourth quarter valued at approximately $27,000. Dimensional Fund Advisors LP boosted its stake in shares of XOMA Royalty by 4.5% during the third quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock valued at $1,124,000 after purchasing an additional 1,269 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Royalty Stock Performance

XOMA Royalty stock opened at $25.53 on Tuesday. XOMA Royalty has a fifty-two week low of $18.35 and a fifty-two week high of $39.92. The company has a debt-to-equity ratio of 1.07, a quick ratio of 3.91 and a current ratio of 3.91. The stock has a market cap of $316.06 million, a P/E ratio of 34.50 and a beta of 0.86. The firm’s fifty day moving average price is $26.02 and its 200-day moving average price is $31.04.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.